Ertugliflozin · Steglatro
Small molecule
Evidence outlook
Approved: Type 2 Diabetes
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Reliable signal
Also approved (1)
- Steglatro is indicated in adults aged 18 years and older with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control: as monotherapy in patients for whom the use of metformin is considered inappropriate due to intolerance or contraindications. in addition to other medicinal products for the treatment of diabetes.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT01986881 NCT01986881 · Type 2 Diabetes Mellitus This trial was randomized, double-blind, and placebo-controlled with over 8,000 participants, giving it strong statistical power, and its primary endpoint was a hard clinical composite (cardiovascular death, non-fatal MI, or non-fatal stroke) rather than a lab surrogate. The trial was designed as a cardiovascular-safety non-inferiority study, and the pre-specified margin was met, with the ertugliflozin-placebo hazard ratio's upper confidence bound (1.114) falling below the 1.3 non-inferiority threshold, demonstrating that ertugliflozin does not increase cardiovascular risk versus placebo in this population. Registry: NCT01986881 | 3 | Time to First Occurrence of MACE (Composite Endpoint of Major Adverse Cardiovascular Events [Cardiovascular Death, Non-fatal Myocardial Infarction or Non-fatal Stroke]) (On-Treatment + 365-day Approach) (Overall Cardiovascular Study) (Up to approximately 6 years); Baseline Hemoglobin A1C (A1C) (Insulin With or Without Metformin Add-on Glycemic Sub-study); Change From Baseline in Hemoglobin A1C (A1C) at Week 18 - Excluding Rescue Approach (Insulin With or Without Metformin Add-on Glycemic Sub-study) (Baseline and Week 18); Baseline Hemoglobin A1C (A1C) (Sulfonylurea Monotherapy Add-on Glycemic Sub-Study); Change From Baseline in Hemoglobin A1C (A1C) at Week 18 - Excluding Rescue Approach (Sulfonylurea Monotherapy Add-on Glycemic Sub-Study) (Baseline and Week 18); Baseline Hemoglobin A1C (A1C) (Metformin With Sulfonylurea Add-on Glycemic Sub-study); Change From Baseline in Hemoglobin A1C (A1C) at Week 18 - Excluding Rescue Approach (Metformin With Sulfonylurea Add-on Glycemic Sub-study) (Baseline and Week 18) 2019-12-27 | Time to First Occurrence of MACE (Composite Endpoint of Major Adverse Cardiovascular Events [Cardiovascular Death, Non-fatal Myocardial Infarction or Non-fatal Stroke]) (On-Treatment + 365-day Approach) (Overall Cardiovascular Study) (Up to approximately 6 years): Ertugliflozin 5 mg (Overall Cardiovascular Study) 3.64 Events per 100 Person-years | Ertugliflozin 15 mg (Overall Cardiovascular Study) 4.16 Events per 100 Person-years | Placebo (Overall Cardiovascular Study) 4.01 Events per 100 Person-years | All Ertugliflozin (Overall Cardiovascular Study) 3.9 Events per 100 Person-years | Reliable signal | link ↗ |
View 7 more trials
NCT01958671 NCT01958671 · Type 2 Diabetes Mellitus This is a randomized, double-blind, placebo-controlled Phase 3 trial with an adequate sample size (461 participants) and a hard clinical endpoint, change in HbA1c, which is the regulator-accepted primary measure for type 2 diabetes. The primary efficacy comparison was met: both ertugliflozin 5 mg and 15 mg produced statistically significant A1C reductions versus placebo at Week 26 (p<0.001 for both). Safety endpoints (adverse events, discontinuations) were balanced among groups. Registry: NCT01958671 | 3 | Change From Baseline In A1C at Week 26 (Baseline and Week 26); Percentage of Participants Experiencing An Adverse Event (AE) (Up to 54 weeks (including 2 weeks following last dose)); Percentage of Participants Discontinuing Study Treatment Due to an AE (Up to 52 weeks) 2016-07-28 | Change in A1C at Week 26 versus placebo: ertugliflozin 5 mg −0.99 percentage points (95% CI −1.22 to −0.76; p<0.001); ertugliflozin 15 mg −1.16 percentage points (95% CI −1.39 to −0.93; p<0.001). | Reliable signal | link ↗ |
NCT02033889 NCT02033889 · Type 2 Diabetes The trial was randomized, double-blind and placebo-controlled, and both ertugliflozin doses lowered HbA1c, the standard measure of diabetes control, significantly more than placebo at Week 26 (p<0.001). The protocol's power calculation called for about 600 participants, and 621 were enrolled. Registry: NCT02033889 | 3 | Change From Baseline in A1C at Week 26 (Excluding Rescue Approach) (Baseline and Week 26); Percentage of Participants Experiencing An Adverse Event (AE) (Including Rescue Approach) (Up to Week 106); Percentage of Participants Discontinuing Study Treatment Due to an AE (Including Rescue Approach) (Up to Week 104) 2017-08-03 | Completed. Key figures are not recorded here; the rationale explains the result. | Reliable signal | link ↗ |
NCT01999218 NCT01999218 · Type 2 Diabetes This was a randomized, double-blind, active-controlled trial with 1,326 participants, and its primary HbA1c comparison for ertugliflozin 15 mg met the prespecified non-inferiority margin versus glimepiride. The grade is moderate because the available record does not report a power or sample-size calculation needed to confirm that the trial was adequately powered. Registry: NCT01999218 | 3 | Change From Baseline in Hemoglobin A1C (A1C) at Week 52: Excluding Rescue Approach (Baseline and Week 52); Percentage of Participants Experiencing An Adverse Event (AE) Up to Week 106; Percentage of Participants Discontinuing Study Treatment Due to an AE Up to Week 104 2017-04-18 | Completed. Key figures are not recorded here; the rationale explains the result. | Partial signal | link ↗ |
NCT02099110 NCT02099110 · Type 2 Diabetes The trial was randomized and double-blind, and adding ertugliflozin to sitagliptin lowered HbA1c, the standard measure of diabetes control, significantly more than sitagliptin alone at both doses (p<0.001), in 1,233 participants. Registry: NCT02099110 | 3 | Change From Baseline in A1C at Week 26: Excluding Rescue Approach (Baseline and Week 26); Percentage of Participants Who Experienced an Adverse Event (AE): Including Rescue Approach (Up to 54 weeks); Percentage of Participants Who Discontinued Study Treatment Due to an AE: Including Rescue Approach (Up to 52 weeks) 2016-05-26 | Completed. Key figures are not recorded here; the rationale explains the result. | Reliable signal | link ↗ |
NCT02036515 NCT02036515 · Type 2 Diabetes The trial was randomized, double-blind and placebo-controlled, and adding either ertugliflozin dose lowered HbA1c, the standard measure of diabetes control, significantly more than adding placebo at Week 26 (p<0.001). The published power calculation planned about 405 participants, and 464 were enrolled. Registry: NCT02036515 | 3 | Change From Baseline in Hemoglobin A1C at Week 26 (Baseline and Week 26); Percentage of Participants Experiencing An Adverse Event (AE) (Up to Week 54); Percentage of Participants Discontinuing Study Treatment Due to an AE (Up to Week 52) 2016-06-06 | Completed. Key figures are not recorded here; the rationale explains the result. | Reliable signal | link ↗ |
NCT02226003 NCT02226003 · Type 2 Diabetes Randomized, double-blind, placebo-controlled trial of 291 participants with change in HbA1c at week 26 as the main endpoint; both ertugliflozin plus sitagliptin groups beat placebo with p<0.001. The published power calculation planned about 300 participants and 291 were enrolled, so the trial fell slightly short of its planned size. Registry: NCT02226003 | 3 | Change From Baseline in Hemoglobin A1C (HbA1C) at Week 26 - Full Analysis Set (FAS Population Excluding Rescue Approach (Baseline and Week 26); Percentage of Participants Who Experienced an Adverse Event (AE) - All Participants as Treated Excluding Rescue Approach (Up to Week 28); Percentage of Participants Who Discontinued Study Medication Due to an AE - All Participants as Treated Excluding Rescue Approach (Up to Week 26) 2016-02-23 | Completed. Key figures are not recorded here; the rationale explains the result. | Partial signal | link ↗ |
NCT01986855 NCT01986855 · Type 2 Diabetes The trial randomized 468 participants to ertugliflozin 5 mg, ertugliflozin 15 mg, or matching placebo and kept participants and investigators blinded. The primary A1C comparison was not statistically significant for either dose (5 mg, p=0.807; 15 mg, p=0.155), and no power calculation is reported in the provided record. Registry: NCT01986855 | 3 | Change From Baseline in A1C at Week 26 - Excluding Rescue Approach (Baseline and Week 26); Percentage of Participants Who Experienced an Adverse Event (AE) (Up to 54 weeks); Percentage of Participants Who Discontinued Study Treatment Due to an AE (Up to 52 weeks) 2016-09-28 | Completed. Key figures are not recorded here; the rationale explains the result. | Partial signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (14)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2 (4)
What this study did
What this study did
What this study did
What this study did
Phase 1 (11)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 4 (9)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Competitive landscape
Other SGLT2 drugs
Bexagliflozin, Canagliflozin, Dapagliflozin, Empagliflozin, Enavogliflozin and 5 more. Compare all 11 SGLT2 drugs
This mechanism is crowded: 10 other tracked programmes target it, none of them ahead of this one.
This drug's own stage for Type 2 Diabetes: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Ertugliflozin (Steglatro): this drug | Approved | Small molecule | SGLT2 | Reliable signal | NCT01986881: Time to First Occurrence of MACE (Composite Endpoint of Major Adverse Cardiovascular Events [Cardiovascular Death, Non-fatal Myocardial Infarction or Non-fatal Stroke]) (On-Treatment + 365-day Approach) (Overall Cardiovascular Study) (Up to approximately 6 years): Ertugliflozin 5 mg (Overall Cardiovascular Study) 3.64 Events per 100 Person-years | Ertugliflozin 15 mg (Overall Cardiovascular Study) 4.16 Events per 100 Person-years | Placebo (Overall Cardiovascular Study) 4.01 Events per 100 Person-years | All Ertugliflozin (Overall Cardiovascular Study) 3.9 Events per 100 Person-years NCT01958671: Change in A1C at Week 26 versus placebo: ertugliflozin 5 mg −0.99 percentage points (95% CI −1.22 to −0.76; p<0.001); ertugliflozin 15 mg −1.16 percentage points (95% CI −1.39 to −0.93; p<0.001). | |
| Acarbose (Precose / Glucobay) | ApprovedUS marketing discontinued | Small molecule | Alpha-glucosidase | not yet graded | No reviewed efficacy summary in this indication | |
| Afrezza | Approved | Peptide | Insulin | Partial signal | NCT04974528: HbA1c change at week 26 (ITT, n=117 vs 113): Afrezza +0.19 vs rapid-acting insulin analog +0.01; difference 0.18 percentage points (95% CI -0.07 to 0.44); non-inferiority (0.4% margin) not met, one-sided adjusted p=0.058. missed NCT01451398: Change in HbA1c from baseline to week 24: Technosphere Insulin + oral agents -0.82% (n=177) vs Technosphere powder (placebo) -0.42% (n=176); difference -0.40% (95% CI -0.57 to -0.23), p<0.0001 (CT.gov posted results). | |
| Alogliptin (Nesina) | Approved | Small molecule | DPP-4 | Partial signal | NCT02856113: Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 26 (Baseline and Week 26): Alogliptin 25 mg 0.091 percentage of HbA1c (Standard Deviation 0.2879) vs Placebo -0.011 percentage of HbA1c (Standard Deviation 0.2809) missed NCT00968708: Percentage of Participants With Primary Major Adverse Cardiac Events (MACE) (From randomization until the adjudication cut-off date of May 31 2013 (maximum time on study was 41 months).): Alogliptin 11.3% vs Placebo 11.8% | |
| Bexagliflozin (Brenzavvy) | Approved | Small molecule | SGLT2 | Reliable signal | NCT02769481: Change From Baseline in HbA1c at Week 60 (Baseline and Week 60): Bexagliflozin -0.7 percentage of glycated hemoglin (Standard Error 0.058) vs Glimepiride -0.66 percentage of glycated hemoglin (Standard Error 0.058) NCT03259789: Change From Baseline in HbA1c at Week 24 for Double-blind Group (Baseline to week 24): Double-blind Group: Bexagliflozin 20 mg -1.09 percentage of HbA1c (Standard Error 0.076) vs Double-blind Group: Placebo -0.56 percentage of HbA1c (Standard Error 0.075) | |
| Canagliflozin (Invokana) | Approved | Small molecule | SGLT2 | Partial signal | NCT03170518: Week 26 HbA1c change: -0.37% canagliflozin 100/300 mg vs +0.39% placebo; least-squares mean difference -0.76 percentage points (95% CI -1.25 to -0.27; p=0.002). NCT02065791: Primary composite outcome (end-stage kidney disease, doubling of serum creatinine, or renal/cardiovascular death): HR 0.70 (95% CI 0.59-0.82; P<0.001), canagliflozin vs placebo, 30% risk reduction | |
| Colesevelam (Welchol) | Approved | Small molecule | Bile acid sequestrant | not yet graded | No reviewed efficacy summary in this indication | |
| Dapagliflozin (Farxiga / Forxiga) | Approved | Small molecule | SGLT2 | Partial signal | NCT01392677: Adjusted Mean Change From Baseline in HbA1c Levels (Baseline to week 24): Dapagliflozin 10mg Plus Metformin Plus Sulfonylurea -0.86 Percent (95% CI -1 to -0.72) vs Placebo Plus Metformin Plus Sulfonylurea -0.17 Percent (95% CI -0.31 to -0.02) NCT00984867: Adjusted Mean Change in HbA1c Levels (Baseline to Week 24): Dapagliflozin -0.45 Percent (95% CI -0.55 to -0.35) vs Placebo 0.04 Percent (95% CI -0.06 to 0.14) | |
| Dulaglutide (Trulicity) | Approved | Peptide | GLP-1 receptor | Reliable signal | NCT03495102: Change in Hemoglobin A1c (HbA1c) From Baseline (Baseline, Week 36): Dulaglutide 1.5 mg -1.53 Percentage of HbA1c (Standard Error 0.04) | Dulaglutide 3 mg -1.71 Percentage of HbA1c (Standard Error 0.04) | Dulaglutide 4.5 mg -1.87 Percentage of HbA1c (Standard Error 0.04) NCT01394952: Number of Participants Who Experienced an Event For Time, From Randomization to First Occurrence of Cardiovascular Death, Non-fatal Myocardial Infarction, or Non-fatal Stroke (a Composite Cardiovascular Outcome) (From randomization to first occurrence or death from any cause or study completion (Median Follow-Up of 5.4 Years)): Dulaglutide 594/4949 vs Placebo 663/4952 | |
| Empagliflozin (Jardiance) | Approved | Small molecule | SGLT2 | Reliable signal | NCT01131676: Time to the First Occurrence of Any of the Following Adjudicated Components of the Primary Composite Endpoint (3-point MACE): CV Death (Including Fatal Stroke and Fatal MI), Non-fatal MI (Excluding Silent MI), and Non-fatal Stroke. (From randomisation to individual end of observation, up to 4.6 years): Empagliflozin 10 mg 10.4% | Empagliflozin 25 mg 10.5% | All Empagliflozin 10.5% vs Placebo 12.1% NCT03429543: HbA1c change at week 26, empagliflozin pooled (10 mg and 25 mg) vs placebo: adjusted mean difference -0.84% (95% CI -1.50 to -0.19), p=0.0116. Treatment failure by week 26 in the small monotherapy cohort: 50.0% vs 60.0%, Fisher p=1.0 (CT.gov posted results). | |
| Glimepiride (Amaryl) | ApprovedUS marketing discontinued | Small molecule | Sulfonylurea receptor (SUR1) | not yet graded | No reviewed efficacy summary in this indication | |
| Glipizide (Glucotrol) | ApprovedUS marketing discontinued | Small molecule | Sulfonylurea receptor (SUR1) | not yet graded | No reviewed efficacy summary in this indication | |
| Glyburide (DiaBeta) | Approved | Small molecule | Sulfonylurea receptor (SUR1) | not yet graded | No reviewed efficacy summary in this indication | |
| Insulin Aspart (NovoLog) | Approved | Peptide | Insulin receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Insulin Aspart (Fiasp) | Approved | Peptide | Insulin receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Insulin Degludec (Tresiba) | Approved | Peptide | Insulin receptor (basal) | Partial signal | NCT00982644: Main Trial (Primary Endpoint): Change in Glycosylated Haemoglobin (HbA1c) After 52 Weeks of Treatment (Week 0, Week 52): IDeg OD -1.06 percentage of glycosylated haemoglobin (Standard Deviation 1.01) vs IGlar OD -1.19 percentage of glycosylated haemoglobin (Standard Deviation 0.97) | |
| Insulin Detemir (Levemir) | ApprovedUS marketing discontinued | Peptide | Insulin receptor (basal) | Partial signal | NCT00856986: Mean Change From Randomisation in Glycosylated Haemoglobin A1c (HbA1c) at Week 26. (Week 0 (Randomisation), week 26): Insulin Detemir + Lira 1.8 -0.51 Percentage point of total HbA1c (Standard Error 0.07) vs Lira 1.8 0.02 Percentage point of total HbA1c (Standard Error 0.07) NCT00283751: HbA1c at 52 weeks: decreased from 8.6% to 7.2% with insulin detemir vs 8.6% to 7.1% with insulin glargine (no significant difference between arms); non-inferiority of detemir to glargine demonstrated. | |
| Insulin Efsitora Alfa (Onswik) | Approved | Protein / enzyme therapeutic | Insulin receptor (basal) | Partial signal | NCT05662332: Change From Baseline in Hemoglobin A1c (HbA1c) [Noninferiority Analysis] (Baseline, Week 52): Efsitora -1.19 Percentage of HbA1c (Standard Error 0.0546) vs Glargine -1.16 Percentage of HbA1c (Standard Error 0.0545) NCT05275400: Change From Baseline in Hemoglobin A1c (HbA1c) [Noninferiority] (Baseline, Week 26): 500 U/mL - Insulin Efsitora -0.81 Percentage of HbA1c (Standard Error 0.0302) vs 100 U/mL - Insulin Degludec -0.72 Percentage of HbA1c (Standard Error 0.0424) | |
| Insulin Glargine (Lantus) | Approved | Peptide | Insulin receptor (basal) | Partial signal | No reviewed efficacy summary in this indication | |
| Insulin Glargine (Basaglar) | Approved | Peptide | Insulin receptor (basal) | Partial signal | NCT03338010: Change From Baseline in Hemoglobin A1c (HbA1c) (LY2963016 to Lantus®) (Baseline, Week 24): LY2963016 -1.27 Percentage of HbA1c (Standard Error 0.043) vs Lantus® -1.23 Percentage of HbA1c (Standard Error 0.062) NCT02302716: Change From Baseline to 24 Weeks in Hemoglobin A1c (HbA1c) (Baseline, 24 weeks): LY2963016 -1.25 Percentage of glycosylated hemoglobin (Standard Error 0.066) vs LANTUS® -1.22 Percentage of glycosylated hemoglobin (Standard Error 0.067) | |
| Insulin Glargine (Toujeo) | Approved | Peptide | Insulin receptor (basal) | Partial signal | NCT01499082: Change in HbA1c From Baseline to Month 6 Endpoint (Baseline, Month 6): HOE901-U300 -0.83 percentage of hemoglobin (Standard Error 0.06) | Lantus -0.83 percentage of hemoglobin (Standard Error 0.061) | |
| Insulin Glulisine (Apidra) | Approved | Peptide | Insulin receptor | Partial signal | NCT00135057: Primary endpoint (A1C change from baseline to week 24, noninferiority of carbohydrate-counting vs a simple fixed-dose algorithm for mealtime insulin glulisine, both arms on insulin glargine as basal): simple algorithm -1.46%, carb count -1.59%; difference -0.13% (95% CI -0.35 to 0.09%), within the pre-specified 0.5% noninferiority margin. Enrollment (281 randomized) matches this NCT exactly. | |
| Insulin Icodec (Awiqli) | Approved | Peptide | Insulin receptor (basal) | Partial signal | NCT06340854: Change in Glycated Haemoglobin (HbA1c) (Week 0, Week 26): Insulin Icodec -0.84 Percentage (%) point (Standard Deviation 0.83) vs Insulin Glargine -0.58 Percentage (%) point (Standard Deviation 0.89) NCT04760626: Change in Glycated Haemoglobin (HbA1c) (Baseline (week 0), week 52): Insulin Icodec -1.68 Percentage of HbA1c (Standard Error 0.09) vs Once Daily Basal Insulin Analogue -1.31 Percentage of HbA1c (Standard Error 0.12) | |
| Insulin Lispro (Humalog) | Approved | Peptide | Insulin receptor | Reliable signal | Featured results are non-efficacy only in this race | |
| Insulin Lispro (Lyumjev) | Approved | Peptide | Insulin receptor | Partial signal | NCT03952143: Change From Baseline in Hemoglobin A1c (HbA1c) (Baseline, Week 26): LY900014 -0.56 Percentage of HbA1c (Standard Error 0.046) vs Insulin Lispro (Humalog) -0.63 Percentage of HbA1c (Standard Error 0.061) NCT03214380: Change From Baseline in Hemoglobin A1c (HbA1c) Efficacy Estimand at Week 26 (Baseline, Week 26): LY900014 -0.38 percentage of HbA1c (Standard Error 0.042) vs Insulin Lispro (Humalog) -0.43 percentage of HbA1c (Standard Error 0.042) | |
| Insulin NPH (Humulin N) | Approved | Peptide | Insulin receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Linagliptin (Tradjenta) | Approved | Small molecule | DPP-4 | Partial signal | NCT01243424: The First 3-point Major Adverse Cardiovascular Events (3P-MACE) (From randomization until individual day of trial completion, up to 432 weeks): Linagliptin 20.7 Events/ 1000 patients-years vs Glimepiride 21.2 Events/ 1000 patients-years NCT03429543: Primary HbA1c outcome at week 26: adjusted mean difference linagliptin versus placebo -0.34 percentage points (95% CI -0.99 to 0.30; p=0.2935). missed | |
| Liraglutide (Victoza) | Approved | Peptide | GLP-1 receptor | Reliable signal | NCT00318461: Change in Glycosylated A1c (HbA1c) at Week 26 (week 0, week 26): Lira 0.6 + Met -0.69 Percentage point of total HbA1c (Standard Error 0.07) | Lira 1.2 + Met -0.97 Percentage point of total HbA1c (Standard Error 0.07) | Lira 1.8 + Met -1 Percentage point of total HbA1c (Standard Error 0.07) vs Met Mono 0.09 Percentage point of total HbA1c (Standard Error 0.09) | Met + Glim -0.98 Percentage point of total HbA1c (Standard Error 0.07) NCT00318422: HbA1c change from baseline at 26 weeks (added to glimepiride): liraglutide 1.2/1.8mg -1.1% (baseline 8.5%) vs placebo +0.2% (baseline 8.4%, P<0.0001) vs rosiglitazone -0.4% (baseline 8.4%, P<0.0001) | |
| Lixisenatide (Adlyxin / Lyxumia) | Approved | Peptide | GLP-1 receptor | Partial signal | NCT00707031: Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24 (Baseline, Week 24): Lixisenatide -0.79 percentage of hemoglobin (Standard Error 0.053) vs Exenatide -0.96 percentage of hemoglobin (Standard Error 0.054) NCT00688701: Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 12 (Baseline, Week 12): Lixisenatide (Two-Step Titration) -0.73 percentage of hemoglobin (Standard Error 0.116) | Lixisenatide (One-Step Titration) -0.85 percentage of hemoglobin (Standard Error 0.119) | |
| Metformin (Glucophage) | ApprovedUS marketing discontinued | Small molecule | AMPK | Reliable signal | NCT00004992: Diabetes incidence: 11.0 (placebo) vs 7.8 (metformin) vs 4.8 (lifestyle) cases per 100 person-years; metformin reduced incidence by 31% vs placebo (95% CI 17-43%) | |
| Pioglitazone (Actos) | Approved | Small molecule | PPAR-gamma | not yet graded | No reviewed efficacy summary in this indication | |
| Pramlintide (Symlin) | ApprovedUS marketing discontinued | Peptide | Amylin receptor | not yet graded | No reviewed efficacy summary in this indication | |
| SAR341402 | Approved | Peptide | Insulin receptor | Partial signal | NCT03211858: Change in Glycated Hemoglobin A1c (HbA1c) From Baseline to Week 26 (Baseline, Week 26): SAR341402 -0.38 percentage of HbA1c (Standard Error 0.042) vs NovoLog/NovoRapid -0.3 percentage of HbA1c (Standard Error 0.041) | |
| Saxagliptin (Onglyza) | ApprovedUS marketing discontinued | Small molecule | DPP-4 | Reliable signal | NCT00121667: Baseline and Change From Baseline in Hemoglobin A1c (A1C) at Week 24 (Baseline, Week 24): Saxagliptin 2.5 mg + Metformin — Baseline Mean: 8.08 percentage of glycosylated hemoglobins (Standard Error 0.07); Adjusted Mean Change from Baseline: -0.59 percentage of glycosylated hemoglobins (Standard Error 0.07) | Saxagliptin 5 mg + Metformin — Baseline Mean: 8.07 percentage of glycosylated hemoglobins (Standard Error 0.06); Adjusted Mean Change from Baseline: -0.69 percentage of glycosylated hemoglobins (Standard Error 0.07) | Saxagliptin 10 mg + Metformin — Baseline Mean: 7.98 percentage of glycosylated hemoglobins (Standard Error 0.08); Adjusted Mean Change from Baseline: -0.58 percentage of glycosylated hemoglobins (Standard Error 0.07) vs Placebo+ Metformin — Baseline Mean: 8.06 percentage of glycosylated hemoglobins (Standard Error 0.07); Adjusted Mean Change from Baseline: 0.13 percentage of glycosylated hemoglobins (Standard Error 0.07) NCT00121641: Hemoglobin A1c (A1C) Changes From Baseline at Week 24 (Baseline, Week 24): Saxagliptin 2.5 mg — Baseline Mean: 7.91 Percentage of glycosylated hemoglobins (Standard Error 0.09); Adjusted Mean Change from Baseline: -0.43 Percentage of glycosylated hemoglobins (Standard Error 0.1) | Saxagliptin 5 mg — Baseline Mean: 7.98 Percentage of glycosylated hemoglobins (Standard Error 0.11); Adjusted Mean Change from Baseline: -0.46 Percentage of glycosylated hemoglobins (Standard Error 0.1) | Saxagliptin 10 mg — Baseline Mean: 7.85 Percentage of glycosylated hemoglobins (Standard Error 0.09); Adjusted Mean Change from Baseline: -0.54 Percentage of glycosylated hemoglobins (Standard Error 0.1) vs Placebo — Baseline Mean: 7.88 Percentage of glycosylated hemoglobins (Standard Error 0.1); Adjusted Mean Change from Baseline: 0.19 Percentage of glycosylated hemoglobins (Standard Error 0.1) | |
| Semaglutide (Ozempic) | Approved | Peptide | GLP-1 receptor | Reliable signal | NCT03819153: Primary composite kidney outcome (kidney failure, sustained >=50% eGFR decline, or death from kidney/cardiovascular causes): 331 first events (semaglutide) vs 410 first events (placebo); HR 0.76 (95% CI 0.66-0.88), P=0.0003. NCT01720446: Time From Randomisation to First Occurrence of a MACE, Defined as Cardiovascular Death, Non-fatal Myocardial Infarction, or Non-fatal Stroke (Time from randomisation up to end of follow-up (scheduled at week 109)): Semaglutide 6.6% vs Placebo 8.9% | |
| Semaglutide (Rybelsus) | Approved | Peptide | GLP-1 receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Sitagliptin (Januvia) | Approved | Small molecule | DPP-4 | Partial signal | NCT00086502: Change From Baseline in HbA1c (Hemoglobin A1C) at Week 24 (Baseline and week 24): Sitagliptin 100 mg -0.85 Percent (95% CI -0.98 to -0.72) vs Placebo -0.15 Percent (95% CI -0.28 to -0.03) NCT00087516: Change From Baseline in A1C at Week 24 (Weeks 0-24): Sitagliptin 100 mg -0.61 Percent (95% CI -0.74 to -0.49) | Sitagliptin 200 mg -0.76 Percent (95% CI -0.88 to -0.64) vs Placebo 0.18 Percent (95% CI 0.06 to 0.3) | |
| Tirzepatide (Mounjaro) | Approved | Peptide | GLP-1/GIP receptor (dual) | Partial signal | NCT04255433: Number of Participants From Randomization to First Occurrence of Death From MACE-3 [Composite Endpoint of Major Adverse Cardiovascular Events Death From Cardiovascular Causes, Myocardial Infarction (MI) or Stroke] (From randomization (week 0) up to week 259): Tirzepatide (MTD) 801/6586 vs 1.5 mg Dulaglutide 862/6579 NCT05260021: Change From Baseline in Hemoglobin A1c (HbA1c) (Pooled Doses of Tirzepatide 5 mg and 10 mg) (Baseline, Week 30): Pooled Doses of Tirzepatide (5 mg, 10 mg) -2.03 percentage of HbA1c (Standard Error 0.165) | Placebo -0.23 percentage of HbA1c (Standard Error 0.229) | |
| Miglitol (Glyset) | US approval withdrawn | Small molecule | Alpha-glucosidase | Partial signal | No reviewed efficacy summary in this indication | |
| Repaglinide (Prandin / NovoNorm) | US approval withdrawn | Small molecule | SUR1 (short-acting) | Partial signal | No reviewed efficacy summary in this indication | |
| Albenatide | Phase 3 | Peptide | GLP-1 receptor | Partial signal | No reviewed efficacy summary in this indication | |
| Aleniglipron | Phase 3 | Small molecule | GLP-1 receptor | Weak signal | NCT05762471: Placebo-adjusted mean weight decrease 6.2% (p<0.0001) at 12 weeks with GSBR-1290 120mg (n=37) vs placebo (n=27); 67% achieved >=6% and 33% >= 10% weight loss vs 0% for placebo | |
| Anagliptin (Suiny) | Phase 3 | Small molecule | DPP-4 | Partial signal | NCT01529528: HbA1c change from baseline to Week 24: anagliptin 100 mg -0.50±0.45%, anagliptin 200 mg -0.51±0.55%, placebo +0.23±0.62% (n=37/33/39, baseline HbA1c 7.14±0.69%); described as significant reductions vs placebo. NCT01529541: Change in HbA1c from baseline to week 24: anagliptin (CWP-0403) -0.85% vs sitagliptin -0.83%; mean difference -0.02% (95% CI -0.22 to 0.18%); non-inferiority established. | |
| ASC30 | Phase 3 | Small molecule | GLP-1 receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Berberine Ursodeoxycholate (HTD1801) | Phase 3 | Small molecule | AMPK pathway / NLRP3 inflammasome (dual) | Reliable signal | NCT06350890: SYMPHONY 1 (NCT06350890, n=408): mean change in HbA1c from baseline at Week 24 with HTD1801 was -1.3%, statistically superior to placebo NCT06353347: SYMPHONY 2 (NCT06353347, n=551): mean change in HbA1c from baseline at Week 24 with HTD1801 was -1.2%, statistically superior to placebo | |
| Berobenatide | Phase 3 | Peptide | GLP-1 receptor | Partial signal | NCT06897202: Dose-dependent body weight decrease up to 10.2% and HbA1c reduction up to 2.2% at the highest weekly dose | |
| BGM0504 | Phase 3 | Peptide | GLP-1/GIP receptor (dual) | not yet graded | No reviewed efficacy summary in this indication | |
| Bofanglutide | Phase 3 | Peptide | GLP-1 receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Cagrilintide | Phase 3 | Peptide | Amylin receptor, Amylin/calcitonin receptor (dual) | not yet graded | No reviewed efficacy summary in this indication | |
| Cagrilintide / Semaglutide (CagriSema) | Phase 3 | Peptide | Amylin receptor, GLP-1 receptor, Amylin/calcitonin receptor (dual) | Reliable signal | NCT05394519: Change in body weight at week 68: -13.7% with CagriSema vs -3.4% with placebo; estimated difference -10.4 percentage points (p<0.001) NCT06534411: Primary endpoints: CagriSema 1.0 mg/1.0 mg superior to tirzepatide 5 mg for weight loss at week 60 (12.4% vs 9.1%) and non-inferior for HbA1c reduction (1.71% vs 1.67%) (2026-09-21). | |
| Chiglitazar (Bilessglu) | Phase 3 | Small molecule | PPAR (pan-agonist) | Reliable signal | NCT04807348: RECAM study, n=533 (178/177/178). LS mean change in HbA1c from baseline at Week 24: -0.91% (32mg), -1.14% (48mg), -0.49% (placebo); both doses vs placebo p<0.001; 48mg vs 32mg p=0.008. NCT02173457: CMAS trial, primary endpoint HbA1c change from baseline at week 24: chiglitazar 32mg and 48mg both non-inferior to sitagliptin 100mg, with treatment differences of -0.04% (95% CI -0.22 to 0.15) and -0.08% (95% CI -0.27 to 0.10) vs sitagliptin (arm sizes n=245/246/248, total 739, matching this trial's design and enrollment of 740) | |
| Cofrogliptin | Phase 3 | Small molecule | DPP-4 | Reliable signal | NCT04564872: HbA1c change from baseline to week 24 (LS mean, SE): cofrogliptin (HSK7653) 10 mg -0.96% (0.063), 25 mg -0.99% (0.064), linagliptin 5 mg -1.07% (0.065); non-inferiority margin of 0.4% met for both cofrogliptin doses vs linagliptin NCT04556851: HbA1c change from baseline to week 24, LS mean difference vs placebo: cofrogliptin (HSK7653) 10 mg -0.63% (95% CI: -0.81, -0.46); 25 mg -0.59% (95% CI: -0.77, -0.42); both p < 0.0001 | |
| Dapagliflozin / Linagliptin (Dapalina) | Phase 3 | Small molecule | SGLT2;DPP-4 | Partial signal | NCT06329674: Change in HbA1c at Week 24: -0.77% AJU-A51 vs +0.10% linagliptin+placebo; LS mean difference -0.88% (95% CI -1.07, -0.68), p<0.0001 | |
| Dorzagliatin (Huatangning) | Phase 3 | Small molecule | Glucokinase | Partial signal | NCT04531631: Acute (first-phase) insulin response to glucose, AIRg, dorzagliatin vs placebo. GCK-MODY group (n=8): 226.1 ± 64.3 vs 179.4 ± 117.7 pmol/L, P = 0.164. Type 2 diabetes group (n=10): -2.3 ± 22.6 vs 31.5 ± 22.1 pmol/L, P = 0.006 (dorzagliatin lower than placebo). missed | |
| Ecnoglutide | Phase 3 | Peptide | GLP-1 receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Efmedaglutide Alfa (Shanmeining) | Phase 3 | Protein / enzyme therapeutic | GLP-1 receptor | Partial signal | NCT06235086: Primary endpoint, HbA1c change at week 28: each TG103 dose non-inferior to dulaglutide 1.5 mg (treatment policy analysis); 15 mg lowered HbA1c 1.38% (CSPC, 2026-09-30). | |
| Efpeglenatide | Phase 3 | Peptide | GLP-1 receptor | Partial signal | NCT03353350: Change in HbA1c from baseline to week 30 vs placebo: efpeglenatide 2 mg -0.5% (95% CI -0.9 to -0.2), p=0.0054; 4 mg -0.8% (-1.2 to -0.5), p<0.0001; 6 mg -1.0% (-1.4 to -0.7), p<0.0001 (AMPLITUDE-M, Rosenstock 2022, Diabetes Care). | |
| Efsubaglutide Alfa | Phase 3 | Protein / enzyme therapeutic | GLP-1 receptor | Reliable signal | NCT04994288: HbA1c change from baseline at week 24 (SUPER-1, phase III stage): 1 mg dose -1.73% (95% CI -20.98,-16.83 mmol/mol), 3 mg dose -2.15% (95% CI -25.68,-21.31 mmol/mol); estimated treatment difference vs placebo -1.26% (1 mg, 95% CI -17.39,-10.06 mmol/mol) and -1.68% (3 mg, 95% CI -22.08,-14.64 mmol/mol), both CIs excluding zero. NCT04998032: HbA1c change from baseline at week 24 (SUPER-2, add-on to metformin): Efsubaglutide 3 mg -1.80% vs placebo -0.74%; estimated treatment difference -1.06% (p<0.001) | |
| Elecoglipron | Phase 3 | Small molecule | GLP-1 receptor | Reliable signal | NCT06579105: HbA1c reduction over 26 weeks: 1.9% with elecoglipron 75 mg (highest dose) vs 0.2% with placebo | |
| Enavogliflozin (Envlo) | Phase 3 | Small molecule | SGLT2 | Reliable signal | NCT04634500: Adjusted mean change in HbA1c at Week 24: enavogliflozin -0.80% vs dapagliflozin -0.75%; treatment difference -0.04% (95% CI -0.21% to 0.12%), meeting the pre-specified non-inferiority margin of 0.35% NCT04632862: Placebo-adjusted mean change in HbA1c from baseline at week 24 in the enavogliflozin 0.3 mg group: -0.99% (95% confidence interval -1.24%, -0.74%). | |
| Enicepatide | Phase 3 | Peptide | GLP-1 receptor, GLP-1/GIP receptor (dual) | not yet graded | No reviewed efficacy summary in this indication | |
| Evogliptin (Suganon) | Phase 3 | Small molecule | DPP-4 | Reliable signal | NCT04170998: Change in HbA1c from baseline: at week 24, LS mean difference evogliptin vs placebo -0.65% (95% CI -0.79 to -0.51, P<0.0001); at week 52, evogliptin -0.59% vs placebo -0.04% (LS mean difference -0.55%, 95% CI -0.71 to -0.39, P<0.0001) NCT02949193: HbA1c change from baseline at 24 weeks: -0.59% with evogliptin 5mg (n=112) vs -0.65% with sitagliptin 100mg (n=110), both add-on to metformin; between-group difference 0.06 percentage points (95% CI -0.10 to 0.22), demonstrating non-inferiority. | |
| Exendin-4 Fc Fusion (JY09) | Phase 3 | Protein / enzyme therapeutic | GLP-1 receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Gemigliptin (Zemiglo) | Phase 3 | Small molecule | DPP-4 | Reliable signal | NCT03842267: LSM difference in HbA1c change at week 24 (gemigliptin add-on vs placebo, on background dapagliflozin + metformin): −0.66% (SE 0.07), 95% CI −0.80% to −0.52%. NCT02831361: Change in HbA1c from baseline at Week 24, between-group mean difference (gemigliptin 50 mg vs placebo, added to insulin ± metformin): -0.7 percentage points (95% CI -0.9 to -0.4), p<0.0001 | |
| Gosogliptin | Phase 3 | Small molecule | DPP-4 | Partial signal | NCT03088670: Primary, HbA1c change at week 12 (monotherapy stage): 8.61% to 7.41% with gosogliptin vs 8.7% to 7.34% with vildagliptin (each p<0.05 vs baseline); the between-group difference was not significant and no non-inferiority test or margin is reported. Week 36 not reported. Target HbA1c <=7.0%: 41% vs 44% (p=0.53). | |
| GZR33 | Phase 3 | Peptide | Insulin receptor (basal) | not yet graded | No reviewed efficacy summary in this indication | |
| Janagliflozin (Huiyoujing) | Phase 3 | Small molecule | SGLT2 | Reliable signal | NCT03811548: Placebo-adjusted HbA1c change at week 24: janagliflozin 25 mg -0.80% (95% CI -0.98 to -0.62), 50 mg -0.88% (95% CI -1.06 to -0.70); P<0.001 for both (Ji et al., Diabetes Obes Metab 2023) | |
| Zibotentan + Dapagliflozin | Phase 3(overall) | Small molecule | Endothelin A receptor, SGLT2 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| DA-2811 | Phase 2 | Small molecule | SGLT2 | not yet graded | No reviewed efficacy summary in this indication | |
| Tofogliflozin (Apleway / Deberza) | Phase 2 | Small molecule | SGLT2 | not yet graded | No reviewed efficacy summary in this indication | |
| Olorigliflozin | Phase 1 | Small molecule | SGLT2 | Weak signal | No reviewed efficacy summary in this indication |
Large race: only the 70 furthest-along competitors are listed; 81 more exist in this indication but aren't shown. Use the search box to compare against any of them.
Compare side by side
3 further pairs are tracked; the rosters on each shared mechanism and indication page list every rival in the race.
Upcoming events
(2 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Steglatro (Ertugliflozin) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.